Management of Low Absolute Neutrophil Count

Classification and Management of Neutropenia

The American College of Physicians and the Infectious Diseases Society of America recommend that management of low absolute neutrophil count should be based on the severity of neutropenia, with prophylactic antimicrobial therapy for severe neutropenia (ANC <0.5 × 10^9/L) and consideration of granulocyte colony-stimulating factor (G-CSF) in specific clinical scenarios 1, 2
For patients with severe neutropenia (ANC <0.5 × 10^9/L), the American College of Physicians recommends implementing broad-spectrum prophylactic antimicrobial therapy, including fluoroquinolone with streptococcal coverage or fluoroquinolone without streptococcal coverage plus penicillin, and adding antiviral therapy (acyclovir or congeners) and antifungal therapy (fluconazole) 1
The Infectious Diseases Society of America guidelines recommend continuing antimicrobial prophylaxis until ANC recovers to ≥0.5 × 10^9/L or patient develops neutropenic fever requiring change in antimicrobial strategy 1, 3

For patients who develop fever (>38.5°C for >1 hour) with ANC <0.5 × 10^9/L, the Infectious Diseases Society of America recommends discontinuing prophylactic fluoroquinolone if being used, initiating empiric therapy directed at gram-negative bacteria (particularly Pseudomonas aeruginosa), and following Infectious Diseases Society of America guidelines for management 1, 2, 3

The American Society of Clinical Oncology recommends using G-CSF for primary prophylaxis when risk of febrile neutropenia >20%, and for reactive treatment when low/intermediate-risk regimens result in grade 3/4 neutropenia 4
The American Society of Clinical Oncology also recommends a standard dose of 5 mcg/kg/day subcutaneously, continuing until ANC recovery (sufficient/stable), and not aiming for ANC >10 × 10^9/L 3

The Infectious Diseases Society of America recommends monitoring for breakthrough infections and adjusting therapy if neutropenic fever develops in patients on antimicrobial prophylaxis 1
The American Society of Clinical Oncology recommends monitoring CBC twice weekly during G-CSF therapy and discontinuing G-CSF if ANC exceeds 10 × 10^9/L 3
The American Society of Clinical Oncology also recommends avoiding gut decontamination with antibiotics unless specifically indicated (e.g., abdominal wound) as altering gut flora may worsen outcomes 1
Long-term G-CSF use may be associated with a small increased risk of myelodysplastic syndrome or acute myeloid leukemia, according to the American Society of Clinical Oncology 4

Patients with ANC <100 cells/μL not receiving antifungal therapy demonstrate statistically higher galactomannan index values, reflecting increased fungal burden, according to the Infectious Diseases Society of America 5

Febrile neutropenia (fever >38.5°C for >1 hour with ANC <0.5 × 10⁹/L) is a medical emergency requiring immediate hospitalization and empiric therapy, as recommended by the European Society for Medical Oncology 6
If apyrexial and ANC ≥0.5 × 10⁹/L, low-risk patients with no identified cause can consider switching to oral antibacterials, as suggested by the European Society for Medical Oncology 6
If still pyrexial at 48 hours, clinically stable patients can continue initial antibacterial therapy, while clinically unstable patients should rotate antibacterial therapy or broaden coverage, as recommended by the European Society for Medical Oncology 6
Discontinue antibacterials when ANC ≥0.5 × 10⁹/L, patient asymptomatic, afebrile for 48 hours, and blood cultures negative, according to the European Society for Medical Oncology 6

Patients with chronic granulomatous disease (CGD) may have repeatedly negative serum galactomannan assays despite invasive aspergillosis, potentially due to lack of angioinvasion or immune complex formation, as noted by the Infectious Diseases Society of America 5
Patients receiving mold-active antifungal prophylaxis may have poor predictive value of serum galactomannan screening, with most positive tests being false positives, according to the Infectious Diseases Society of America 5